160 related articles for article (PubMed ID: 29670079)
21. Cystatin C prevents degeneration of rat nigral dopaminergic neurons: in vitro and in vivo studies.
Xu L; Sheng J; Tang Z; Wu X; Yu Y; Guo H; Shen Y; Zhou C; Paraoan L; Zhou J
Neurobiol Dis; 2005 Feb; 18(1):152-65. PubMed ID: 15649706
[TBL] [Abstract][Full Text] [Related]
22. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
[TBL] [Abstract][Full Text] [Related]
23. Pre-administration of BAX-inhibiting peptides decrease the loss of the nigral dopaminergic neurons in rats.
Ma C; Pan Y; Yang Z; Meng Z; Sun R; Wang T; Fei Y; Fan W
Life Sci; 2016 Jan; 144():113-20. PubMed ID: 26612350
[TBL] [Abstract][Full Text] [Related]
24. Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson's disease.
Xue YQ; Zhao LR; Guo WP; Duan WM
Neuroscience; 2007 May; 146(3):1245-58. PubMed ID: 17363174
[TBL] [Abstract][Full Text] [Related]
25. Pathogenic Upregulation of Glial Lipocalin-2 in the Parkinsonian Dopaminergic System.
Kim BW; Jeong KH; Kim JH; Jin M; Kim JH; Lee MG; Choi DK; Won SY; McLean C; Jeon MT; Lee HW; Kim SR; Suk K
J Neurosci; 2016 May; 36(20):5608-22. PubMed ID: 27194339
[TBL] [Abstract][Full Text] [Related]
26. Decreased expression of serum- and glucocorticoid-inducible kinase 1 (SGK1) promotes alpha-synuclein increase related with down-regulation of dopaminergic cell in the Substantia Nigra of chronic MPTP-induced Parkinsonism mice and in SH-SY5Y cells.
Yeo S; Sung B; Hong YM; van den Noort M; Bosch P; Lee SH; Song J; Park SK; Lim S
Gene; 2018 Jun; 661():189-195. PubMed ID: 29604467
[TBL] [Abstract][Full Text] [Related]
27. Dissociation of progressive dopaminergic neuronal death and behavioral impairments by Bax deletion in a mouse model of Parkinson's diseases.
Kim TW; Moon Y; Kim K; Lee JE; Koh HC; Rhyu IJ; Kim H; Sun W
PLoS One; 2011; 6(10):e25346. PubMed ID: 22043283
[TBL] [Abstract][Full Text] [Related]
28. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
[TBL] [Abstract][Full Text] [Related]
29. Targeted Overexpression of α-Synuclein by rAAV2/1 Vectors Induces Progressive Nigrostriatal Degeneration and Increases Vulnerability to MPTP in Mouse.
Song LK; Ma KL; Yuan YH; Mu Z; Song XY; Niu F; Han N; Chen NH
PLoS One; 2015; 10(6):e0131281. PubMed ID: 26114655
[TBL] [Abstract][Full Text] [Related]
30. Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease.
Marinova-Mutafchieva L; Sadeghian M; Broom L; Davis JB; Medhurst AD; Dexter DT
J Neurochem; 2009 Aug; 110(3):966-75. PubMed ID: 19549006
[TBL] [Abstract][Full Text] [Related]
31. Montelukast treatment protects nigral dopaminergic neurons against microglial activation in the 6-hydroxydopamine mouse model of Parkinson's disease.
Jang H; Kim S; Lee JM; Oh YS; Park SM; Kim SR
Neuroreport; 2017 Mar; 28(5):242-249. PubMed ID: 28178069
[TBL] [Abstract][Full Text] [Related]
32. RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson's disease by a mechanism involving mammalian target of rapamycin inactivation.
Malagelada C; Ryu EJ; Biswas SC; Jackson-Lewis V; Greene LA
J Neurosci; 2006 Sep; 26(39):9996-10005. PubMed ID: 17005863
[TBL] [Abstract][Full Text] [Related]
33. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
34. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease.
McCoy MK; Martinez TN; Ruhn KA; Szymkowski DE; Smith CG; Botterman BR; Tansey KE; Tansey MG
J Neurosci; 2006 Sep; 26(37):9365-75. PubMed ID: 16971520
[TBL] [Abstract][Full Text] [Related]
35. Adaptation within mitochondrial oxidative phosphorylation supercomplexes and membrane viscosity during degeneration of dopaminergic neurons in an animal model of early Parkinson's disease.
Kuter K; Kratochwil M; Berghauzen-Maciejewska K; Głowacka U; Sugawa MD; Ossowska K; Dencher NA
Biochim Biophys Acta; 2016 Apr; 1862(4):741-753. PubMed ID: 26844379
[TBL] [Abstract][Full Text] [Related]
36. GDNF Overexpression from the Native Locus Reveals its Role in the Nigrostriatal Dopaminergic System Function.
Kumar A; Kopra J; Varendi K; Porokuokka LL; Panhelainen A; Kuure S; Marshall P; Karalija N; Härma MA; Vilenius C; Lilleväli K; Tekko T; Mijatovic J; Pulkkinen N; Jakobson M; Jakobson M; Ola R; Palm E; Lindahl M; Strömberg I; Võikar V; Piepponen TP; Saarma M; Andressoo JO
PLoS Genet; 2015 Dec; 11(12):e1005710. PubMed ID: 26681446
[TBL] [Abstract][Full Text] [Related]
37. [Estrogen protects the dopaminergic neurons in substantia nigra against damage induced by 6-hydroxydopamine].
Meng JL; Ma YY; Luo HY; Kong SZ; He YW; Dong BC; Wu SH; He M
Sheng Li Xue Bao; 2008 Jun; 60(3):369-74. PubMed ID: 18560728
[TBL] [Abstract][Full Text] [Related]
38. Repulsive Guidance Molecule a (RGMa) Induces Neuropathological and Behavioral Changes That Closely Resemble Parkinson's Disease.
Korecka JA; Moloney EB; Eggers R; Hobo B; Scheffer S; Ras-Verloop N; Pasterkamp RJ; Swaab DF; Smit AB; van Kesteren RE; Bossers K; Verhaagen J
J Neurosci; 2017 Sep; 37(39):9361-9379. PubMed ID: 28842419
[TBL] [Abstract][Full Text] [Related]
39. Direct and retrograde transduction of nigral neurons with AAV6, 8, and 9 and intraneuronal persistence of viral particles.
Löw K; Aebischer P; Schneider BL
Hum Gene Ther; 2013 Jun; 24(6):613-29. PubMed ID: 23600720
[TBL] [Abstract][Full Text] [Related]
40. Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease.
Mandel RJ; Snyder RO; Leff SE
Exp Neurol; 1999 Nov; 160(1):205-14. PubMed ID: 10630205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
